Review



epigenetic compound screen  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    TargetMol epigenetic compound screen
    Epigenetic Compound Screen, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Epigenetics+Compound+Library/pmc12830624-24-13-30
    Average 93 stars, based on 26 article reviews
    epigenetic compound screen - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Drug discovery:

    Article Title: Identification of targetable epigenetic vulnerabilities for uveal melanoma
    Article Snippet: .. Given the global epigenetic changes elicited by BAP1 loss, we performed a comprehensive epigenetic compound screen on UM cells, using a well-characterized drug library consisting of 932 cell-permeable, small-molecule modulators (TargetMol, L1200, July 2022; Supplementary Data ). ..

    Article Title: Identification of targetable epigenetic vulnerabilities for uveal melanoma.
    Article Snippet: .. Epigenetic compound screening identifies new vulnerabilities in UM Given the global epigenetic changes elicited by BAP1 loss, we performed a comprehensive epigenetic compound screen on UM cells, using a well-characterized drug library consisting of 932 cell-permeable, small-molecule modulators (TargetMol, L1200, July 2022; Supplementary Data 1). .. Epigenetic compound screening identifies new vulnerabilities in UM Given the global epigenetic changes elicited by BAP1 loss, we performed a comprehensive epigenetic compound screen on UM cells, using a well-characterized drug library consisting of 932 cell-permeable, small-molecule modulators (TargetMol, L1200, July 2022; Supplementary Data 1).

    other:

    Article Title: Identification of targetable epigenetic vulnerabilities for uveal melanoma
    Article Snippet: Fetal bovine serum (FBS, Neuromics, Edina, MN, USA) used in cell media was heat-inactivated in a water bath at 57°C for 10 minutes.



    Similar Products

    epigenetics compound library  (TargetMol)
    94
    TargetMol epigenetics compound library
    Epigenetics Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/10__1016_slash_j__apsb__2026__06__020-48-1-5
    Average 94 stars, based on 1 article reviews
    epigenetics compound library - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    epigenetic targeting  (TargetMol)
    94
    TargetMol epigenetic targeting
    Epigenetic Targeting, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/10__1016_slash_j__apsb__2026__05__020-185-0-14
    Average 94 stars, based on 1 article reviews
    epigenetic targeting - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    targetmol epigenetic inhibitors  (TargetMol)
    94
    TargetMol targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-139-10-10
    Average 94 stars, based on 1 article reviews
    targetmol epigenetic inhibitors - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    380 targetmol epigenetic inhibitors  (TargetMol)
    94
    TargetMol 380 targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    380 Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-78-19-20
    Average 94 stars, based on 1 article reviews
    380 targetmol epigenetic inhibitors - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    sgc epigenetic compounds  (TargetMol)
    94
    TargetMol sgc epigenetic compounds
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Sgc Epigenetic Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-78-16-20
    Average 94 stars, based on 1 article reviews
    sgc epigenetic compounds - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    rna epigenetic modifications  (Biomark Inc)
    86
    Biomark Inc rna epigenetic modifications
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Rna Epigenetic Modifications, supplied by Biomark Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/epigenetic+modifications+rna/pm41928252-984-26-39
    Average 86 stars, based on 1 article reviews
    rna epigenetic modifications - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    epigenetic modifications  (Abbott Laboratories)
    86
    Abbott Laboratories epigenetic modifications
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Modifications, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/epigenetic+modifications/pm41866754-363-1-32
    Average 86 stars, based on 1 article reviews
    epigenetic modifications - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    epigenetic inhibitors  (TargetMol)
    94
    TargetMol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/pm41713838-53-7-15
    Average 94 stars, based on 1 article reviews
    epigenetic inhibitors - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    epigenetic modifications  (Epigenomics ag)
    90
    Epigenomics ag epigenetic modifications
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Modifications, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/epigenetic+modifications/pmc12204941-61-11-16
    Average 90 stars, based on 1 article reviews
    epigenetic modifications - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: The screening library comprised 619 compounds, including SGC epigenetic compounds, TargetMol epigenetic inhibitors, and FDA-approved oncology drugs ( ).

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control